The lawsuit alleges that Taxotere causes permanent and complete baldness (alopecia). While hair loss is a frequent complication linked to chemotherapy medications, permanent baldness isn't.To qualify in one of these scenarios, the person has to have been treated with Taxotere between 2006-2016 and should have undergone hair loss for six weeks or more.
The suspect in this Taxotere suit is a worldwide pharmaceutical business, Sanofi-Aventis.The manufacturer failed to warn patients and physicians about the possibility of permanent baldness.
The organization's sales force falsely asserted that Taxotere was significantly more powerful than its rival, Taxol, that does not lead to permanent hair loss.
If you or a loved one have taken Taxotere as part of your chemotherapy and experienced alopecia, the hair loss could be permanent and you want to file a report against this drug you should hire a taxotere hair loss lawyer.
The patients in this study received different therapies, such as Taxotere. Sedlacek discovered that 6.3 percent of the patients that had been treated with Taxotere undergone hair development less than 50% of the speed before treatment. This lasted up to seven decades following chemotherapy therapy solved.
In 2012, a study by the Annals of Oncology noted that "permanent and severe alopecia is a recently reported complication," of this medication regimen involving Taxotere.